FDA APPROVED

For the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy1

FDA APPROVED

For the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy1

Clearly
for Her

CIMZIA®—clearer skin that lasts,
so she can plan ahead1,18,19

Co-primary endpoints were PASI 75 and PGA 0/1. A majority of patients responded at Week 16, and responder rates were maintained to Week 48 with 200 mg every other week maintenance dosing. (N=1020. 113 female subjects treated with 200 mg Q2W)1,5,18,19

See the trials

CIMZIA has 6 approved indications1

PSO

Moderate to Severe Plaque Psoriasis in adults who are candidates for systemic therapy or phototherapy

CD

Moderately to Severely Active Crohn’s Disease if response to conventional therapy is inadequate

RA

Moderately to Severely Active Rheumatoid Arthritis

PsA

Active Psoriatic Arthritis

AS

Active Ankylosing Spondylitis

NR axSpA

Non-radiographic Axial Spondyloarthritis

Sign up for a UCB Representative visit today